Fosun Pharma subsidiary's chronic constipation drug application accepted by NMPA

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its controlled subsidiary, Shanghai Zhaohui Pharmaceutical Co., Ltd., has had its drug registration application for Compound Polyethylene Glycol (3350) Electrolyte Powder accepted by the National Medical Products Administration. This chemical drug is intended for the treatment of chronic constipation, excluding cases caused by organic diseases.

As of October 2025, the Fosun Pharma group has invested approximately RMB 6.21 million in research and development for its series of Compound Polyethylene Glycol (3350) Electrolyte Powder products, including this specific drug. According to IQVIA CHPA data, the market for Compound Polyethylene Glycol (3350) Electrolyte Powder in mainland China was approximately RMB 873 million in 2024.

The company cautioned that commercial production of the drug is contingent upon obtaining drug registration approval and other necessary clearances. The acceptance of this application currently has no material impact on the group's performance. The final market success of the drug will depend on various factors including demand, market competition, and sales channels.